Albuterol
Active ingredient: Albuterol Sulfate
In short: Albuterol Inhalation Solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease).
What is Albuterol used for?
Albuterol Inhalation Solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease).
âš Boxed warning (FDA's strongest warning)
As with other inhaled beta-adrenergic agonists, Albuterol Inhalation Solution can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs, Albuterol Inhalation Solution should be discontinued immediately and alternative therapy instituted. It should be noted that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister or vial.
The use of beta-adrenergic bronchodilators alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents (e.g., corticosteroids).
Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of Albuterol Inhalation Solution than usual, this may be a marker of destabilization of asthma and requires re-evaluation of the patient and the treatment regimen, giving special consideration of the possible need for anti-inflammatory treatment (e.g., corticosteroids).
Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs and with the home use of nebulizers. It is, therefore, essential that the physician instruct the patient in the need for further evaluation, if his/her asthma becomes worse.
Albuterol Inhalation Solution, like other beta-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms. …
Albuterol dosage
The usual starting dosage for patients 2 to 12 years of age is 1.25 mg or 0.63 mg of Albuterol Inhalation Solution administered 3 or 4 times daily, as needed, by nebulization. More frequent administration is not recommended.
To administer 1.25 mg or 0.63 mg of albuterol, use the entire contents of one unit-dose vial (3 mL of 1.25 mg or 0.63 mg inhalation solution) by nebulization. Adjust nebulizer flow rate to deliver Albuterol Inhalation Solution over 5 to 15 minutes.
The use of Albuterol Inhalation Solution can be continued as medically indicated to control recurring bouts of bronchospasm. During this time most patients gain optimum benefit from regular use of the inhalation solution.
Patients 6 to 12 years of age with more severe asthma (baseline FEV1 less than 60% predicted), weight > 40 kg, or patients 11 to 12 years of age may achieve a better initial response with the 1.25 mg dose.
Albuterol Inhalation Solution has not been studied in the setting of acute attacks of bronchospasm. A 2.5 mg dose of albuterol provided by a higher concentration product (2.5 mg albuterol per 3 mL) may be more appropriate for treating acute exacerbations, particularly in children 6 years old and above.
If a previously effective dosage regimen fails to provide the usual relief, medical advice should be sought immediately, as this is often a sign of seriously worsening asthma which would require reassessment of therapy.
The drug compatibility (physical and chemical), clinical efficacy and safety of Albuterol Inhalation Solution, when mixed with other drugs in a nebulizer have not been established.
The safety and efficacy of Albuterol Inhalation Solution have been established in clinical trials when administered using the Pari LC Plusâ„¢ nebulizer and Pari PRONEBâ„¢ compressor. The safety and efficacy of Albuterol Inhalation Solution when administered with other nebulizer systems have not been established.
Albuterol Inhalation Solution should be administered via jet nebulizer connected to an air compressor with adequate air flow, equipped with a mouthpiece or suitable face mask.
Warnings & precautions
Do not take this medicine if: Albuterol Inhalation Solution is contraindicated in patients with a history of hypersensitivity to any of its components.
Large doses of intravenous albuterol have been reported to aggravate pre-existing diabetes mellitus and ketoacidosis. As with other beta-agonists, inhaled and intravenous albuterol may produce a significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring potassium supplementation.
The action of Albuterol Inhalation Solution may last up to six hours, and therefore it should not be used more frequently than recommended. Do not increase the dose or frequency of medication without consulting your physician. If you find that treatment with Albuterol Inhalation Solution becomes less effective for symptomatic relief, your symptoms become worse, and/or you need to use the product more frequently than usual, you should seek medical attention immediately. All asthma medication should only be used under the supervision and direction of a physician. Common effects with medications such as Albuterol Inhalation Solution include palpitations, chest pain, rapid heart rate, tremor, or nervousness.
If you are pregnant or nursing, contact your physician about the use of Albuterol Inhalation Solution. Effective and safe use of Albuterol Inhalation Solution includes an understanding of the way it should be administered.
If the solution in the vial changes color or becomes cloudy, you should not use it.
The drug compatibility (physical and chemical), clinical efficacy, and safety of Albuterol Inhalation Solution, when mixed with other drugs in a nebulizer, has not been established.
See illustrated Patient’s Instructions for Use. …
Albuterol side effects
Adverse events reported in >1% of patients receiving Albuterol Inhalation Solution and more frequently than in patients receiving placebo in a four-week double-blind study are listed in the following table.
1.25 mg Albuterol Inhalation Solution (N=115) | 0.63 mg Albuterol Inhalation Solution (N=117) | Placebo
(N=117)
Asthma Exacerbation | 13 | 11.1 | 8.5
Otitis Media | 4.3 | 0.9 | 0
Allergic Reaction | 0.9 | 3.4 | 1.7
Gastroenteritis | 0.9 | 3.4 | 0.9
Cold Symptoms | 0 | 3.4 | 1.7
Flu Syndrome | 2.6 | 2.6 | 1.7
Lymphadenopathy | 2.6 | 0.9 | 1.7
Skin/Appendage Infection | 1.7 | 0 | 0
Urticaria | 1.7 | 0.9 | 0
Migraine | 0.9 | 1.7 | 0
Chest Pain | 0.9 | 1.7 | 0
Bronchitis | 0.9 | 1.7 | 0.9
Nausea | 1.7 | 0.9 | 0.9
There was one case of ST segment depression in the 1.25 mg Albuterol Inhalation Solution treatment group.
No clinically relevant laboratory abnormalities related to Albuterol Inhalation Solution administration were seen in this study.
Metabolic acidosis has been reported after the use of albuterol inhalation solution. Because this reaction is reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate its frequency or establish a causal relationship to drug exposure.
About this medicine
Albuterol inhalation solution, USP is a sterile, clear, colorless solution of the sulfate salt of racemic albuterol, albuterol sulfate. Albuterol sulfate is a relatively selective beta2 - adrenergic bronchodilator . The chemical name for albuterol sulfate is α1 [(tert-butylamino) methyl]-4-hydroxy-m-xylene-α, α’-diol sulfate (2:1) (salt), and its established chemical structure is as follows:
The molecular weight of albuterol sulfate is 576.7 and the empirical formula is (C13H21NO3)2 • H2SO4. Albuterol sulfate is a white crystalline powder, soluble in water and slightly soluble in ethanol. The World Health Organization recommended name for albuterol is salbutamol.
Albuterol Inhalation Solution, USP is supplied in two strengths in unit dose vials. Each unit dose vial contains either 0.63 mg of albuterol equivalent to 0.75 mg of albuterol sulfate or 1.25 mg of albuterol equivalent to 1.5 mg of albuterol sulfate with sodium chloride, edetate disodium (EDTA), and sulfuric acid in a 3-mL isotonic, sterile, aqueous solution. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 9e6e982b-7dfe-45b8-aa76-754e8d2a8ef6. Read the full official label on DailyMed.
Related medicines
Montelukast Fluticasone Hydroxyzine Fluticasone and Salmeterol Budesonide and Formoterol Fluticasone and Umeclidinium and Vilanterol Azelastine Fluticasone and Vilanterol